A new study has shown that a microbicide gel that is highly effective
in blocking infection by HIV in a non-human primate model, could be the
key to lasting protection from the virus which causes AIDS.
In the paper published in the PLOS Pathogens – an open access
journal,Dereuddre-Bosquet and colleagues from the European Combined
Highly Active Anti-Retroviral Microbicides, CHAARM, Consortium describe
the gel’s key ingredient, which are small peptides engineered to present
a decoy to bind up the virus and prevent it from entering and infecting
the cells of the body. Because this is a gel it can be topically
applied and could represent a powerful preventative agent against sexual
transmission of HIV.
Worldwide, the scientific community is working on development of a
vaccine against HIV. Meanwhile, research is also focused on the
reduction of the spread of the virus by the application of a microbicide
gel to protect users during intercourse which is a time of first exposure to virus. To date, few treatments that block virus entry have shown promising protection.
The researchers engineered peptides named “miniCD4s” because they
mimic the CD4 receptor used by HIV to gain entry into immune cells of
the body. The study shows that the miniCD4s blocks HIV entry into
isolated cells in a dish and tissue models that mimic mucous membranes
which are points of virus entry.
Then they formulated miniCD4s at 0.3 percent in a microbicide gel
that was vaginally applied to six female cynomolgus macaques monkeys for
one hour before the animals were given a high dose of the virus also in
the vagina.
This dose would ordinarily make the animals highly infected but
instead, five of the six were completely protected from HIV infection.
No trace of virus was found in any body tissue. They were also unable
to detect any antibodies to the virus in the plasma of the animals,
indicating that the virus was completely repelled and there was full
protection.
This study provides a proof of principle that for a promising
strategy for the prevention and protection against HIV transmission
during sexual intercourse. Importantly, the protection was demonstrated
in a non human primate model which represents an essential step prior
needed to progress to a prospective clinical trial
source:vanguardngr
0 comments:
Post a Comment